PUBLICATIONS

Effectiveness and normal tissue toxicity of Auger electron (AE) radioimmunotherapy (RIT) with [111 In]In-Bn-DTPA-nimotuzumab in mice with triple-negative or trastuzumab-resistant human breast cancer xenografts that overexpress EGFR

Authors: Chan C, Fonge H, Lam K, Reilly R

Year: 2020 Published in: Nuclear Medicine and Biology

Advanced breast cancer treatment with hR3 monoclonal antibody combined with doxorubicin and cyclophosphamide, phase I

Authors: Center of Molecular Immunology

Year: 2006 Published in: RPCEC

Clinical observational study of Nimotuzumab combined with concurrent chemoradiotherapy in the treatment of locally advanced cervical cancer

Authors: Chen J, Cao YJ, Zhu L, Zhang BL, Liu ZY, Hou HL, Chai YL, Wang P

Year: 2021 Published in: Zhonghua Yi Xue Za Zhi

Nimotuzumab Combined with Irradiation Enhances the Inhibition to the HPV16 E6-Promoted Growth of Cervical Squamous Cell Carcinoma

Authors: Xu Z, Shu H, Zhang F, Luo W, Li Y, Chu J, Zhao Q, Lv Y

Year: 2020 Published in: Frontiers in Oncology

 

Specific Immunotherapy in Advanced Cervical-Uterine Cancer Using Humanized Monoclonal Antibody Nimotuzumab and CIMAvax-EGF® Therapeutic Vaccine
Authors: Ruiz-Lorente R , Alfonso S , Santiesteban E , Sánchez Y, Camacho K , Mendoza E , Viada C , Ortiz R , Carreño I , Troche M , Cepeda M , Vals A , Cabrera L , Gorte A , Batista D , Domenech M, Santiesteban Y, Santiesteban Y, Estevez D, García-Viamontes J, Mico C, Ramos-Suzarte M
Year: 2021 Published in: Journal of Cancer Therapy

Clinical efficacy and safety of nimotuzumab plus chemotherapy in patients with advanced colorectal cancer: a retrospective analysis

Authors: Bai SX, Zhang RR, Chen WH, Dong HM, Wang G, Li XK, Wang W

Year: 2020 Published in: Scientific Reports

Very long-term of survival, 5 years and more in diffuse intrinsic pontine brainstem gliomas in children and adolescents treated with Radiotherapy and Nimotuzumab

Authors: Alert J, Chon I, Valdes J, Ropero R, Perez M, Garcia D, Forteza M, Avila J

Year: 2021 Published in: International Journal of Radiology & Radiation Therapy

 

Phase 2 study of safety and efficacy of nimotuzumab in pediatric patients with progressive diffuse intrinsic pontine glioma

Authors: Bartels U, Wolff J, Gore L, Dunkel I, Gilheeney S, Allen J, Goldman S, Yalon M, Packer RJ, Korones DN, Smith A, Cohen K, Kuttesch J, Strother D, Baruchel S, Gammon J, Kowalski M, Bouffet E

Year: 2014 Published in: Neurology

 

Nimotuzumab and radiotherapy for treatment of newly diagnosed diffuse intrinsic pontine glioma (DIPG): a phase III clinical study

Authors: Fleischhack G, Siegler S, Massimo M, Warmuth-Metz M, Biassoni V, Reuter D, Bach F, Janssen G

Year: 2009 Published in: Journal of Neuro-Oncology

Nimotuzumab, a promising therapeutic monoclonal for treatment of tumors of epithelial origin

Authors: Ramakrishnan MS, Eswaraiah A, Crombet T, Piedra P, Saurez G, Iyer H, Arvind AS

Year: 2009 Published in: Monoclonal antibodies

 

A phase I study of 99mTc-hR3 (DiaCIM), a humanized immunoconjugate directed towards the epidermal growth factor receptor.

Authors: Vallis KA, Reilly RM, Chen P, Oza A, Hendler A, Cameron R, Hershkop M, Iznaga-Escobar N, Ramos-Suzarte M, Keane P

Year: 2002 Published in: Nuclear Medicine Communications

Randomized phase II trial of nimotuzumab plus irinotecan versus irinotecan alone as second-line therapy for patients with advanced gastric cancer
Authors: Satoh T, Lee KH, Rha SY, Sasaki Y, Park SH, Komatsu Y, Yasui H, Kim TY, Yamaguchi K, Fuse N, Yamada Y, Ura T, Kim SY, Munakata M, Saitoh S, Nishio K, Morita S, Yamamoto E, Zhang Q, Kim JM, Kim YH, Sakata Y

Year: 2014 Published in: Gastric Cancer

Nimotuzumab therapy in the treatment of pediatric central nervous system tumors: single-center experience
Authors: Susam-Sen H, Varan A, Bajin I, Gocmen R, Aydin B, Yalcin B, Kurucu N, Kutluk T, Bayhan T, Akyuz C

Year: 2021 Published in: Naunyn-Schmiedeberg's Archives of Pharmacology

 

Reported outcomes of children with newly diagnosed high-grade gliomas treated with nimotuzumab and irinotecan

Authors: Sirachainan N, Boongird A, Swangsilpa T, Klaisuban W, Lusawat A, Hongeng S

Year: 2017 Published in: Child's nervous system

 

Nimotuzumab in Management of Brain Stem Glioma: A Case Report

Authors: Kumar K, Selvakumar P, Rathinam K

Year: 2017 Published in: Journal of Cancer Therapy

 

Safety and effectiveness of nimotuzumab in high grade glioma patients. Phase iv study results

Authors: Giselle S, Silvia NS, Rolando U, Patricia P, Jorge AA, Bárbara I., Yanet G, Rafael D, Carolina T, María T, Hector G, Julio S, Daysi C, María A, Lisett P, Agustin L         

Year: 2016 Published in: International Journal of Current Medical and Pharmaceutical Research

 

Final results of a randomized phase III trial of nimotuzumab for the treatment of newly diagnosed glioblastoma in addition to standard radiation and chemotherapy with temozolomide versus standard radiation and temoziolamide

Authors: Westpal M, Heese O, Steinbach JP, Schnell O, Schackert G, Mehdorn M, Schulz D, Reuter D, Geletneky K, Metz MM, Bach F, Pietsch T

Year: 2015 Published in: Journal of Clinical Oncology

 

Radiotherapy plus the anti-EGFR mAb nimotuzumab or placebo for the treatment of high-grade glioma patients

Authors: Ramos TC, Solomon MT, Selva JC, Figueredo J, Vaquer J, Toledo C, Salva NQ, Dominguez R, Alert J, Marinello JJ, Catala M, Griego MG, Luaces PL, Iznaga N, Bach F

Year: 2012 Published in: Journal of Clinical Oncology

 

An open label, prospective, multicentric study to evaluate the safety and efficacy of BIOMAb-EGFR TM (Nimotuzumab) as induction and maintenance therapy in combination with radiotherapy plus temozolomide (Concomitant & Adjuvant) in Indian patients with glioblastoma multiforme

Authors: Jalali R, Julka PK, Anand AK, Bhavsar D, Singhal N, Naik R

Year: 2011 Published in: Neuro-oncology

 

Treatment of high-grade glioma patients with the humanized anti-epidermal growth factor receptor (EGFR) antibody h-R3: report from a phase I/II trial

Authors: Ramos TC, Figueredo J, Catala M, González S, Selva JC, Cruz TM, Toledo C, Silva S, Pestano Y, Ramos M, Leonard I, Torres O, Marinello P, Pérez R, Lage A

Year: 2006 Published in: Cancer biology and therapy

Phase II study of nimotuzumab (TheraCim-hR3) concurrent with cisplatin/radiotherapy in patients with locally advanced head and neck squamous cell carcinoma

Authors: Ang MK, Montoya JE, Tharavichitkul E, Lim C, Tan T, Wang LY, Wee J, Soong YL, Fong KW, Ng QS, Tan DS, Toh CK, Tan EH, Lim WT

Year: 2021 Published in: Head & Neck

Addition of Nimotuzumab to Standard TPF Regimen in Locally Advanced Head and Neck Cancer: A Single Institutional Study

Authors: Samuel LK, Vinu S, Hrishi V, Beulah ET, Radheshyam N

Year: 2021 Published in: Journal of Oncology

Retrospective analysis of nimotuzumab vs chemotherapy in locally advanced head and neck squamous cell carcinoma patients receiving concurrent radiotherapy

Authors: Rakesh S, Suresh A, Mallik S, Dattatreya

Year: 2021 Published in: International Journal of Medical Science And Diagnosis Research

Nimotuzumab for Patients With Inoperable Cancer of the Head and Neck

Authors: Ramos TC, Fernandez BM, Herrera ZM, Escobar NI

Year: 2020 Published in: Frontiers in Oncology

Prognostic and predictive significance of nuclear HIF1α expression in locally advanced HNSCC patients treated with chemoradiation with or without nimotuzumab

Authors: Patel U, Pandey M, Kannan S, Samant TA, Gera P, Mittal N, Rane S, Patil A, Noronha V, Joshi A, Patil VM, Prabhash K, Mahimkar MB

Year: 2020 Published in: British journal of cancer

Combined Nimotuzumab with Chemoradiotherapy for Locally Advanced Head and Neck Squamous Cell Carcinoma

Authors: Hoa NTT, Huy HQ

Year: 2020 Published in: Cureus

Nimotuzumab with intensity-modulated radiation therapy in unresectable and platinum-ineligible locally advanced head-and-neck cancer

Authors: Srinivas KS, Sundaram R, Divyambika CV, Chaudhari S

Year: 2020 Published in: South Asian Journal of Cancer

Response to nivolumab combining radiotherapy and nimotuzumab in metastatic oral squamous cell carcinoma patient with strong PD-L1 expression: a case report

Authors: Tang X, Chen S, Sui Q, Li X, Liu Z, Zhu F, Ding J, Yao Y, Jiang B, He Y

Year: 2020 Published in: Annals of translational medicine

Efficacy and tolerability of nimotuzumab in combination with chemotherapy in recurrent and metastatic squamous cell carcinoma of head and neck at a cancer center in Northern India

Authors: Yadav A, Goyal P, Agrawal CR, Bothra SJ, Jain P, Choudhury KD, Gupta SK, Sharma M, Bajaj R, Upadhyay A, Dash P, Doval DC

Year: 2020 Published in: Indian Journal of Cancer

Nimotuzumab Dosing and Outcomes in Locally Advanced Head and Neck Cancer

Authors: Joshi A, Patil VM, Noronha V, Abhyankar A, Menon N, Prabhash K

Year: 2019 Published in: Clinical Oncology

A randomized phase 3 trial comparing nimotuzumab plus cisplatin chemoradiotherapy versus cisplatin chemoradiotherapy alone in locally advanced head and neck cancer

Authors: Patil VM, Noronha V, Joshi A, Agarwal J, Ghosh-Laskar S, Budrukkar A, Murthy V, Gupta T, Mahimkar M, Juvekar S, Arya S, Mahajan A, Agarwal A, Purandare N, Rangarajan V, Balaji A, Chaudhari SV, Banavali S, Kannan S, Bhattacharjee A, D'Cruz AK, Chaturvedi P, Pai PS, Chaukar D, Pantvaidya G, Nair D, Nair S, Deshmukh A, Thiagarajan S, Mathrudev V, Manjrekar A, Dhumal S, Maske K, Bhelekar AS, Nawale K, Chandrasekharan A, Pande N, Goel A, Talreja V, Simha V, Srinivas S, Swami R, Vallathol DH, Dsouza H, Shrirangwar S, Turkar S, Abraham G, Thanky AH, Patel U, Pandey MK, Prabhash K

Year: 2019 Published in: Cancer

Results of a randomized phase III study of nimotuzumab in combination with concurrent radiotherapy and cisplatin versus radiotherapy and cisplatin alone, in locally advanced squamous cell carcinoma of the head and neck

Authors: Vijay Maruti Patil, Vanita Noronha, Amit Joshi, Jaiprakash Agarwal, Sarbani Ghosh Laskar, Ashwini Budrukkar, Vedang Murthy, Sadhana Kannan, Atanu Bhattacharjee, Pankaj Chaturvedi, P. S. Pai, Devendra Chaukar, Anil K D'cruz, S Juvekar, Aparna Manjrekar, Vijayalakshmi Mathrudev, Kavita Prakash Nawale, Arti Bhelekar, Shripad Dinanath Banavali, Kumar Prabhash

Year: 2018 Published in: Journal of Clinical Oncology

Nimotuzumab Induces NK Cell Activation, Cytotoxicity, Dendritic Cell Maturation and Expansion of EGFR-Specific T Cells in Head and Neck Cancer Patients

Authors: Mazorra Z, Lavastida A, Concha-Benavente F, Valdés A, Srivastava RM, García-Bates TM, Hechavarría E, González Z, González A, Lugiollo M, Cuevas I, Frómeta C, Mestre BF, Barroso MC, Crombet T, Ferris RL

Year: 2017 Published in: Frontiers in Pharmacology

Retrospective analysis to assess the feasibility of escalated dose of nimotuzumab in patients with locally advanced head and neck cancer

Authors: Huilgol NG, Nair A, Chaudhari S, Pawar D

Year: 2017 Published in: Journal of Radiation and Cancer Research

Nimotuzumab and Intensity Modulated Radiation Therapy (IMRT) in the Concurrent Setting of Locally Advanced Head and Neck Cancers: Early Results of a Prospective Trial in India

Authors: K. Talapatra, M. Deshpande, S. Goyle, D. Majumder, S. Badhwar

Year: 2016 Published in: International Journal of Radiation Oncology, Biology, Physics

An open-label, randomized, study of h-R3mAb (nimotuzumab) in patients with advanced (stage III or IVa) squamous cell carcinoma of head and neck (SCCHN): Four-year survival results from a phase IIb study

Authors: Babu KG, Viswanath L, Reddy BK, Shenoy K, Shenoy A, Naveen T, Joseph B, Vidyasagar MS, Bonanthaya R, Pasha CT, Bapsy PP, Aravind AS, Eswaraiah A, Gupt N

Year: 2010 Published in:  Journal of Clinical Oncology

Nimotuzumab plus radiotherapy for unresectable squamous-cell carcinoma of the head and neck

Authors: Rodríguez MO, Rivero TC, del Castillo Bahi R, Muchuli CR, Bilbao MA, Vinageras EN, Alert J, Galainena JJ, Rodríguez E, Gracias E, Mulén B, Wilkinson B, de Armas EL, Pérez K, Pineda I, Frómeta M, Leonard I, Mullens V, Viada C, Luaces P, Torres O, Iznaga N, Crombet T

Year: 2010 Published in:  Cancer biology and therapy

Use of the humanized anti-epidermal growth factor receptor monoclonal antibody h-R3 in combination with radiotherapy in the treatment of locally advanced head and neck cancer patients

Authors: Crombet T, Osorio M, Cruz T, Roca C, del Castillo R, Mon R, Iznaga-Escobar N, Figueredo R, Koropatnick J, Renginfo E, Fernández E, Alvárez D, Torres O, Ramos M, Leonard I, Pérez R, Lage A

Year: 2004 Published in:  Jounal of Clinical Oncology

Nimotuzumab combined with radiotherapy for the treatment of hypopharyngeal cancer - A case report from a tertiary cancer center

Authors: Nagarajan A, Sakthivelu A, Santhanaraman N, Ravichandar R

Year: 2021 Published in:  Journal of clinical and translational research

 

Nimotuzumab Combined with Induction Chemotherapy and Concurrent Chemoradiotherapy in Unresectable Locally Advanced Hypopharyngeal Carcinoma: A Single Institution Experience in China

Authors: Tian X, Xuan Y, Wu R, Gao S

Year: 2020 Published in:  Cancer Management and Research

Efficacy of nimotuzumab (hR3) conjugated with 131I or 90Y in laryngeal carcinoma xenograft mouse model

Authors: Nguyen TT, Ho A, Nguyen T, Nguyen T, Bui V, Nguyen TB, Dang HQ, Nguyen DK, Nguyen TN, Nguyen LT

Year: 2021 Published in:  International Journal of Radiation Biology

Concurrent chemoradiotherapy with or without nimotuzumab in locally advanced squamous cell lung cancer: a phase 2 randomized trial

Authors: Qiu B, Wang D, Li QW, Wu Y, Guo S, Jiang XB, Jang JL, Guo JY, Liu FJ, Chu C, Li C, Zhang J, Liu YM, Hu YH, Liu H

Year: 2021 Published in:  International Journal of Radiation Oncology

 

PUB125 Clinical Observation of Nimotuzumab Combined with Chemotherapy as First Line Therapy for Advanced Lung Squamous Cell Carcinoma

Authors: Si X, Zhang X, Wang H, Wang M, Li Z

Year: 2016 Published in:  Journal of Thoracic Oncology

Nimotuzumab plus chemoradiotherapy versus placebo plus chemoradiotherapy in patients with locally advanced nasopharyngeal carcinoma (NPC): A prospective, randomized-controlled, double-blinded, multicenter phase III clinical trial

Author: Yan Sun, Chaosu Hu, Qin Lin, et al.

Year: 2022 Published in: ASCO Oral Abstract Session

Use of nimotuzumab combined with cisplatin in treatment of nasopharyngeal carcinoma and its effect on expressions of VEGF and MMP-2

Authors: Qu L, Wang JH, Du JX, Kang P, Niu XQ, Yin LZ

Year: 2021 Published in:  Clinical and translational oncology

Nimotuzumab, an Anti-EGFR Monoclonal Antibody, in the Treatment of Nasopharyngeal Carcinoma

Authors: Liang R, Yang L, Zhu X

Year: 2021 Published in:  Cancer control : journal of the Moffitt Cancer Center

Effect of nimotuzumab and PF induction chemotherapy combined with concurrent chemoradiotherapy in treating locally advanced nasopharyngeal carcinoma.

Authors: Gao M, Yuan T, Zhang F

Year: 2021 Published in:  Journal of B.U.ON. : Official Journal of the Balkan Union of Oncology

Effectiveness and cost-effectiveness analysis of nimotuzumab for the radiotherapy of locoregionally advanced nasopharyngeal carcinoma

Authors: Fei Z, Xu T, Li M, Chen T, Li L, Qiu X, Chen C

Year: 2020 Published in:  Radiation Oncology

Nimotuzumab plus platinum-based chemotherapy versus platinum-based chemotherapy alone in patients with recurrent or metastatic nasopharyngeal carcinoma

Authors: Zhu Y, Yang S, Zhou S, Yang J, Qin Y, Gui L, Shi Y, He X

Year: 2020 Published in:  Therapeutic advances in medical oncology

Effects of Different Chemoradiotherapy Regimens on Early Survival Outcomes in Patients with Locally Advanced Nasopharyngeal Carcinoma

Authors: Li N, Li P

Year: 2020 Published in:  Sichuan Da Xue

Efficacy and safety of nimotuzumab with neoadjuvant chemotherapy followed by concurrent chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma

Authors: Wang F, Jiang C, Ye Z, Sun Q, Liu T, Xu M, Wu P, Shi K, Long B, Rihito A, Masoto S, Fu Z

Year: 2017 Published in:  Oncotarget

Induction chemotherapy followed by concurrent chemoradiation and nimotuzumab for locoregionally advanced nasopharyngeal carcinoma: preliminary results from a phase II clinical trial

Authors: Huang JF, Zhang FZ, Zou QZ, Zhou LY, Yang B, Chu JJ, Yu JH, Zhang HW, Yuan XP, Tai GM, Liu FJ, Ma CC

Year: 2017 Published in:  Oncotarget

A retrospective paired study: efficacy and toxicity of nimotuzumab versus cisplatin concurrent with radiotherapy in nasopharyngeal carcinoma

Authors: Li HM, Li P, Qian YJ, Wu X, Xie L, Wang F, Zhang H, Liu L

Year: 2016 Published in:  Biomed Central Cancer

Nimotuzumab combined with concurrent chemoradiotherapy benefits patients with advanced nasopharyngeal carcinoma

Authors: Li Z, Li Y, Yan S, Fu J, Zhou Q, Huang X, Shen L

Year: 2016 Published in:  OncoTargets and therapy

Multi-center phase II clinical trial of humanized anti-epidermal factor receptor monoclonal antibody h-R3 combined with radiotherapy for locoregionally advanced nasopharyngeal carcinoma

Authors: Huang X, Yi J, Gao L, Xu G, Jin J, Yang W, Lu T, Wu S, Wu R, Hu W, Xie W, Han F, Gao Y, Gao J, Pan J, Chen C, Lang J, Li T, Dong Y, Fu Y, Fan L, Li B, Li J, Wang X, Chen B, Gao X, Zhang P, Wu X, Hu B

Year: 2007 Published in:  Zhonghua Zhong Liu Za Zhi

Phase 2 Study of Nimotuzumab in Combination with Concurrent Chemoradiotherapy in Patients With Locally Advanced Non–Small-Cell Lung Cancer

Authors: Yamamoto N, Harada H, Okamoto I, Karukai Y, Masuda N, Hayakawa K, Satouchi M, Soejima T, Seto T, Sasaki T, Tsubouchi H, Nakagawa K

Year: 2021 Published in:  Clinical Lung Cancer

 

Dual Targeting of the Epidermal Growth Factor Receptor Using Combination of Nimotuzumab and Erlotinib in Advanced Non-Small-Cell Lung Cancer with Leptomeningeal Metastases: A Report of Three Cases

Authors: Xu H, Zhou L, Lu Y, Su X, Cheng P, Li D, Gao H, Li H, Yuan W, Zhang L, Zhang T

Year: 2020 Published in:  Onco Targets and Therapy

 

A randomized, phase II study of gefitinib alone versus nimotuzumab plus gefitinib after platinum-based chemotherapy in advanced non-small cell lung cancer (KCSG LU12-01)

Authors: Kim HR, Jang JS, Sun JM, Ahn MJ, Kim DW, Jung I, Lee KH, Kim JH, Lee DH, Kim SW, Cho BC

Year: 2017 Published in:  Oncotarget

 

A phase I study of nimotuzumab plus docetaxel in chemotherapy-refractory/resistant patients with advanced non-small-cell lung cancer

Authors: Zhao J, Zhuo M, Wang Z, Duan J, Wang Y, Wang S, An T, Wu M, Wang J

Year: 2016 Published in:  Chinese Journal of Cancer Research

 

Prolonged overall survival of patients with leptomeningeal carcinomatosis from non-small cell lung cancer

Authors: Ju Y, Sun S, Wang J, Jiao S

Year: 2016 Published in:  Journal of cancer research and therapeutics

 

Nimotuzumab plus chemotherapy versus chemotherapy alone in advanced non-small cell lung cancer: a multicenter, randomized, open-label Phase II study

Authors: Babu KG, Prabhash K, Vaid AK, Sirohi B, Dwakar RB, Rao R, Kar M, Malhotra H, Nag S, Goswami C, Raina V, Mohan R

Year: 2014 Published in:  Onco Targets and Therapy

Nimotuzumab plus concurrent chemo-radiotherapy versus chemo-radiotherapy in unresectable locally advanced esophageal squamous cell carcinoma (ESCC): Interim analysis from a prospective, randomized-controlled, double-blinded, multicenter, and phase III clinical trial (NXCEL1311 Study)

Author: Xue Meng, Anping Zheng, Jun Wang, et al.

Year: 2022 Published in: ASCO Poster Discussion Session

A systematic analysis in efficacy and safety of nimotuzumab combined with concurrent chemoradiotherapy in treatment of advanced esophageal cancer

Authors: Liu C, Li M, Zhao G

Year: 2021 Published in: Journal of Clinical Medicine in Practice 

Radiotherapy combined with nimotuzumab for elderly esophageal cancer patients: A phase II clinical trial

Authors: Yang, X., Zhai, Y., Bi, N., Zhang, T., Deng, L., Wang, W., Wang, X., Chen, D., Zhou, Z., Wang, L., & Liang, J

Year: 2021 Published in: Chinese journal of cancer research

Nimotuzumab, an EGFR‑targeted antibody, promotes radiosensitivity of recurrent esophageal squamous cell carcinoma

Authors: Yu Y, Guan H, Jiang L, Li X, Xing L, Sun X

Year: 2020 Published in: International Journal of Oncology

Case Report: Primary and Acquired Resistance Mechanisms of Nimotuzumab in Advanced Esophageal Squamous Cell Carcinoma Revealed by Targeted Sequencing

Authors: Sun D, Yan W, Zhu H, Liu Q, Hou H

Year: 2020 Published in: Frontiers in Oncology

Treatment of esophageal cancer with multiple liver metastases: a case experience of sustained complete response

Authors: Wang J, Xu C

Year: 2020 Published in: The Journal of International Medical Research

Nimotuzumab Plus Paclitaxel and Cisplatin as a 1 st-Line Treatment for Esophageal Cancer: Long Term Follow-up of a Phase II Study

Authors: Zhang X, Jia J, Lu M, Wang X, Gong J, Li J, Li J, Li Y, Zhang X, Lu Z, Zhou J, Yu J, Sun Z, Yang Y, Liu C, Xiao Y, Shen L

Year: 2019 Published in: Journal of Cancer

A randomised phase II study of chemoradiotherapy with or without nimotuzumab in locally advanced oesophageal cancer: NICE trial

Authors: Castro Jr G, Segalla JG, Azevedo SJ, Andrade CJ, Grabarz D, Franca BAL, Giglio AD, Lazaretti NS, Alvares MN, Pedrini JL, Kussumoto C, Neto JN, Forones NM, Fernandes HJ, Borges G, Girotto G, Silva ID, Maluf-Filho F, Skare NG

Year: 2018 Published in: European Journal of Cancer

Nimotuzumab combined with concurrent chemoradiotherapy in Japanese patients with esophageal cancer: A phase I study

Authors: Kato K, Ura T, Koizumi W, Iwasa S, Katada C, Azuma M, Ishikura S, Nakao Y, Onuma H, Muro K

Year: 2018 Published in: Cancer science

Nimotuzumab Combined with Chemotherapy is a Promising Treatment for Locally Advanced and Metastatic Esophageal Cancer

Authors: Han X, Lu N, Pan Y, Xu J

Year: 2017 Published in: Medical science monitor

Nimotuzumab in Combination with Chemoradiotherapy in a Case of Locally Advanced Oesophageal Malignancy

Authors: Sharma JB

Year: 2016 Published in: Journal of Case Reports

Combined nimotuzumab with chemoradiotherapy in patients with locally advanced or metastatic esophageal squamous cell carcinoma: A retrospective study

Authors: Lai X, Gu Q, Zheng X, Liu G, Feng W, Lin X, Mao W

Year: 2016 Published in: Journal of cancer research and therapeutics

Nimotuzumab plus paclitaxel and cisplatin as the first line treatment for advanced esophageal squamous cell cancer: A single centre prospective phase II trial

Authors: Lu M, Wang X, Shen L, Jia J, Gong J, Li J, Li J, Li Y, Zhang X, Lu Z, Zhou J, Zhang

Year: 2016 Published in: Cancer science

High-dose nimotuzumab improves the survival rate of esophageal cancer patients who underwent radiotherapy

Authors: Wang C, Fu X, Cai X, Wu X, Hu X, Fan M, Xiang J, Zhang Y, Chen H, Jiang G, Zhao K

Year: 2018 Published in: OncoTargets and therapy

Treatment of malignant, non-resectable, epithelial origin esophageal tumours with the humanized anti-epidermal growth factor antibody nimotuzumab combined with radiation therapy and chemotherapy

Authors: Ramos-Suzarte M, Lorenzo-Luaces P, Lazo NG, Perez ML, Soriano JL, Gonzalez CE, Hernadez IM, Albuerne YÁ, Moreno BP, Alvarez ES, Callejo IP, Alert J, Martell JA, Gonzalez YS, Gonzalez YS, Astudillo de la Vega H, Ruiz-Garcia EB, Ramos TC

Year: 2012 Published in: Cancer biology and therapy

Nimotuzumab-cisplatin-radiation versus cisplatin-radiation in HPV negative oropharyngeal cancer

Authors: Noronha V, Patil VM, Joshi A, Mahimkar M, Patel U, Pandey MK, Chandrasekharan A, Dsouza H, Bhattacharjee A, Mahajan A, Sabale N, Agarwal JP, Ghosh-Laskar S, Budrukkar A, D'Cruz AK, Chaturvedi P, Pai PS, Chaukar D, Nair S, Thiagarajan S, Banavali S, Prabhash K

Year: 2020 Published in: Oncotarget

Nimotuzumab Plus Gemcitabine Improves Survival in KRAS Wild-Type Pancreatic Cancer

Author: Kristie L. Kahl

Year: 2022 Published in: ASCO Annual Meeting

Nimotuzumab May Improve Overall Survival in Patients With KRAS Wild-Type Advanced Pancreatic Cancer

Author: The ASCO Post Staff

Year: 2022 Published in: The ASCO Post

Gemcitabine combined with the monoclonal antibody nimotuzumab is an active first-line regimen in KRAS wildtype patients with locally advanced or metastatic pancreatic cancer: a multicenter, randomized phase IIb study

Authors: Schultheis B, Reuter D, Ebert MP, Siveke J, Kerkhoff A, Berdel WE, Hofheinz R, Behringer DM, Schmidt WE, Goker E, Dosso, SD, Kneba M, Yalcin S, Overkamp F, Schlegel F, Dommach M, Rohrberg R, Steinmetz T, Bulitta M, Strumberg D

Year: 2017 Published in:  Annals of Oncology

EGFR inhibition is effective against KRAS-wild-type disease

Authors: Sidaway P

Year: 2017 Published in:  Nature Reviews Clinical Oncology

Phase II study of nimotuzumab, a humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody, in patients with locally advanced or metastatic pancreatic cancer

Authors: Strumberg D, Schultheis B, Scheulen ME, Hilger RA, Krauss J, Marschner N, Lordick F, Bach F, Reuter D, Mross K

Year: 2012 Published in:  Investigational New Drugs

Final report of a phase II trial of nimotuzumab in the treatment of refractory and relapsed high-grade gliomas in children and adolescents

Authors: U. Bode , S. Buchen , M. Warmuth-Metz , T. Pietsch , F. Bach , G. Fleischhack

Year: 2006 Published in:  Journal of Clinical Oncology

Metastases Due to Prostate Cancer

Authors: Quian YP, Crombet T, Batista JF, Prats A, Perera A

Year: 2016 Published in:  Clinical Nuclear Medicine

A phase I, pharmacokinetic and pharmacodynamic study of nimotuzumab in Japanese patients with advanced solid tumors

Authors: Okamoto W, Yoshino T, Takahashi T, Okamoto I, Ueda S, Tsuya A, Boku N, Nishio K, Fukuoka M, Yamamoto N, Nakagawa K

Year: 2013 Published in:  Cancer Chemotherapy Pharmacology

A dose-escalation phase I trial of nimotuzumab, an antibody against the epidermal growth factor receptor, in patients with advanced solid malignancies

Authors: You B, Brade A, Magalhaes JM, Siu LL, Oza A, Lovell S, Wang L, Hedley DW, Nicacio LV, Chen EX

Year: 2011 Published in:  Investigational New Drugs